Zolgensma heads up spate of US approvals
The US FDA granted seven approvals in two days last week, including an eagerly awaited thumbs-up for Novartis’s gene therapy Zolgensma.
AAN 2019 – Viela Bio takes on Alexion in neuromyelitis optica
The Astrazeneca spinout is plugging data with its rare disease contender inebilizumab, but Alexion’s Soliris is one step ahead.
Pressure on Abbvie's pipeline grows
Abbvie will need more than Skyrizi and upadacitinib to fill a Humira-shaped hole, and there are a few early-stage candidates it reckons could fit the bill.
Mustang and the bubble boy bubble
The value of Mustang Bio has tripled on data on its immune deficiency gene therapy. But investors might be too keen – and also too late.
Boehringer pushes pipeline progress
The notoriously secretive German pharma company Boehringer Ingelheim has made much of a new drive towards transparency, but there are still things it would rather keep to…
US shutdown dampens first-quarter flotations
Biopharma IPOs dipped in the opening months of 2019, but numbers look fairly healthy despite January's US government closure.
Peanut therapy makers face pricing pushback
An Icer report questioning the cost effectiveness of Aimmune and DBV's peanut allergy projects is yet another reason to be cautious about the companies'…
Upcoming events – Pfizer and Glycomimetics await sickle cell data and Biocryst tries again
Rivipansel needs to help sickle cell patients leave hospital sooner and BCX7353 faces established hereditary angioedema agents.
Galapagos flies with more Finch data
Filgotinib could be the safest Jak inhibitor yet, but Galapagos will need to make the most of this as it squares up to Abbvie.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.